title: 3,4-dideoxyglucosone-3-ene in peritoneal dialysis fluids infused into the peritoneal cavity cannot be found in plasma.
abstract: OBJECTIVE
  Glucose degradation products (GDPs) are important for the outcome of peritoneal dialysis (PD) treatment. The most cytotoxic GDP found in conventionally manufactured fluids, 3,4-dideoxyglucosone-3-ene (3,4-DGE), may in addition be recruited from 3-deoxyglucosone (3-DG). What happens with the GDPs in the fluid infused into patients during PD is not known. We investigated whether 3,4-DGE and 3-DG in PD fluid can be found in plasma during treatment.
  
  
  METHODS
  Patients on PD were dialyzed with a conventional PD fluid containing 43 micromol/L 3,4-DGE and 281 micromol/L 3-DG. Parallel experiments were performed in rats and in vitro with human plasma. The rats were dialyzed with a PD fluid containing 100 micromol/L 3,4-DGE and 200 micromol/L 3-DG.
  
  
  RESULTS
  The 3,4-DGE concentration in the peritoneum declined at a much higher rate during the dwell than did the 3-DG concentration. However, 3,4-DGE was not detected in the plasma of patients or of rats during dialysis. The 3-DG concentration in plasma peaked shortly after infusion of fluid into the peritoneal cavity. The 3,4-DGE concentration during experimental incubation in plasma declined rapidly; the 3-DG concentration declined only 10% as rapidly (or less).
  
  
  CONCLUSIONS
  During dialysis, 3,4-DGE could not be detected in plasma of either PD patients or rats, presumably because of its high reactivity. On the other hand, 3-DG may pass through the membrane and be detected in the blood.
authors.affiliation: Gambro AB, University of Lund, Lund, Sweden. martin.erixon@gambro.com
authors.forename: Martin
authors.initials: M
authors.lastname: Erixon
authors.forename: Anders
authors.initials: A
authors.lastname: Wieslander
authors.forename: Torbjörn
authors.initials: T
authors.lastname: Lindén
authors.forename: Ola
authors.initials: O
authors.lastname: Carlsson
authors.forename: Jan Ake
authors.initials: JA
authors.lastname: Jönsson
authors.forename: Ole
authors.initials: O
authors.lastname: Simonsen
authors.forename: Per
authors.initials: P
authors.lastname: Kjellstrand
mesh_terms: D000818:Animals; D002851:Chromatography, High Pressure Liquid; D015314:Dialysis Solutions / Q000008:administration & dosage / Q000493:pharmacokinetics*; D004195:Disease Models, Animal; D017127:Glycation End Products, Advanced / Q000378:metabolism; D024981:Glycogen Phosphorylase / Q000037:antagonists & inhibitors; D006801:Humans; D007274:Injections, Intraperitoneal; D007676:Kidney Failure, Chronic / Q000378:metabolism* / Q000628:therapy; D008297:Male; D010530:Peritoneal Dialysis / Q000379:methods*; D010537:Peritoneum / Q000187:drug effects / Q000378:metabolism; D011753:Pyrones / Q000008:administration & dosage / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar
chemical_list: C504711:3,4-dideoxyglucosone-3-ene; D015314:Dialysis Solutions; D017127:Glycation End Products, Advanced; D011753:Pyrones; D024981:Glycogen Phosphorylase